Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitors in Acute Ischemic Stroke Undergoing Endovascular Therapy
NCT07174375Phase 3Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab, alirocumab in ischemic stroke, sponsored by Nanfang Hospital, Southern Medical University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
evolocumabalirocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07174375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174375.